# I’m weighing recovery claims against ordinary life on Peptides Blog.

[Peptides Blog](/) · [Archive](/#archive) · [Topics](/#topics) · [About](/about)

October 27, 2026

![An adult standing upright on a paddleboard in still blue water close to shore.](/pb-quiet-morning-0e3fea6c17b1/one-quiet-paddle.webp)

A free morning on the water is the goal in this post, not evidence of a peptide’s effect.

With a modest ambition, I’m opening Peptides Blog: a free morning spent doing something fun. A gentle paddle or a game with friends. No medal required. That’s the sort of life a “recovery” claim brings to mind.

But what did the research actually show? I want to know whether people got back to an activity they enjoyed, and what problems came with treatment. A result from a rat’s knee needs to stay a result from a rat’s knee.

## The everyday goal is the part I care about

Amino acids link together to make a peptide. Proteins are built from those same small units, in longer chains. The name tells us about its chemistry. It doesn’t tell us whether something works or [where it fits in medical care](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers).

GHK-Cu is one example: a small peptide holding copper. In a [study of rats after knee-ligament surgery](https://pubmed.ncbi.nlm.nih.gov/25731775/), it briefly reduced looseness in the knee. The benefit didn’t last. The study couldn’t show a clear difference in walking or in the force needed to break the repaired ligament.

I can see why that experiment interests people. I can’t read it as evidence that a person will recover faster. The photograph here shows the sort of morning I’m talking about; it doesn’t show a treatment result.

[Read the complete recovery post](/recovery-claims)

## More from October 27

October 27, 2026

### [I put the GLP-1 medicines in a different conversation](/glp-1-medicines)

Semaglutide and tirzepatide have approved uses and trials in people. That matters. So do stomach side effects and what happens when treatment stops. I want those parts of the story on the same page.

[Continue reading](/glp-1-medicines)

October 27, 2026

### [I keep skin-care hopes apart from an energy claim](/skin-and-energy)

GHK-Cu and NAD+ both attract big claims about ageing. I want to know what changed for a person. A skin-cell experiment can explain an idea without proving a cream works. Higher blood NAD+ can be interesting without proving someone feels better. And despite often sharing the same conversation, NAD+ isn’t a peptide at all.

[Continue reading](/skin-and-energy)

October 27, 2026

### [A changed signal doesn’t finish the story for me](/signal-claims)

A hormone reading can change without answering the question that brought someone to the research. I’m keeping that question in view for sermorelin, selank and kisspeptin.

[Continue reading](/signal-claims)

## Every published post

Four posts, all published on October 27, 2026. This is the archive so far.

- October 27, 2026 [I want recovery to mean getting back out there](/recovery-claims)

- October 27, 2026 [I put the GLP-1 medicines in a different conversation](/glp-1-medicines)

- October 27, 2026 [I keep skin-care hopes apart from an energy claim](/skin-and-energy)

- October 27, 2026 [A changed signal doesn’t finish the story for me](/signal-claims)

## Follow a question

Different compounds, different evidence. These links open the published posts, with the relevant everyday question still attached.

- [Recovery and the word peptide](/recovery-claims)

- [Semaglutide and tirzepatide](/glp-1-medicines)

- [GHK-Cu and NAD+](/skin-and-energy)

- [Sermorelin, selank and kisspeptin](/signal-claims)

---

I keep Peptides Blog a reading guide, with no medical practice, pharmacy service or goods for sale.

[References](/references) · [Contact](/contact)

© 2026 Peptides Blog